MEDIFAST INC (MED) Stock Fundamental Analysis

NYSE:MED • US58470H1014

10.43 USD
-0.22 (-2.07%)
At close: Feb 26, 2026
10.43 USD
0 (0%)
After Hours: 2/26/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

MED gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 36 industry peers in the Personal Care Products industry. While MED has a great health rating, there are worries on its profitability. MED does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • MED had negative earnings in the past year.
  • MED had a positive operating cash flow in the past year.
  • MED had positive earnings in 4 of the past 5 years.
  • Each year in the past 5 years MED had a positive operating cash flow.
MED Yearly Net Income VS EBIT VS OCF VS FCFMED Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M

1.2 Ratios

  • The Return On Assets of MED (-7.53%) is worse than 72.22% of its industry peers.
  • MED has a Return On Equity (-9.39%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -7.53%
ROE -9.39%
ROIC N/A
ROA(3y)8.43%
ROA(5y)22.37%
ROE(3y)13.65%
ROE(5y)42.92%
ROIC(3y)N/A
ROIC(5y)N/A
MED Yearly ROA, ROE, ROICMED Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

1.3 Margins

  • Looking at the Gross Margin, with a value of 71.33%, MED is in the better half of the industry, outperforming 69.44% of the companies in the same industry.
  • In the last couple of years the Gross Margin of MED has remained more or less at the same level.
  • MED does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0%
GM growth 5Y-0.9%
MED Yearly Profit, Operating, Gross MarginsMED Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • MED does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MED has been increased compared to 1 year ago.
  • Compared to 5 years ago, MED has less shares outstanding
  • MED has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MED Yearly Shares OutstandingMED Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
MED Yearly Total Debt VS Total AssetsMED Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • MED has an Altman-Z score of 4.42. This indicates that MED is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 4.42, MED belongs to the best of the industry, outperforming 86.11% of the companies in the same industry.
  • MED has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.42
ROIC/WACCN/A
WACC8.69%
MED Yearly LT Debt VS Equity VS FCFMED Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 4.69 indicates that MED has no problem at all paying its short term obligations.
  • MED has a better Current ratio (4.69) than 83.33% of its industry peers.
  • MED has a Quick Ratio of 4.22. This indicates that MED is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 4.22, MED belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.69
Quick Ratio 4.22
MED Yearly Current Assets VS Current LiabilitesMED Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The earnings per share for MED have decreased strongly by -132.02% in the last year.
  • The Revenue for MED has decreased by -35.96% in the past year. This is quite bad
  • Measured over the past years, MED shows a very negative growth in Revenue. The Revenue has been decreasing by -16.22% on average per year.
EPS 1Y (TTM)-132.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-650%
Revenue 1Y (TTM)-35.96%
Revenue growth 3Y-37.74%
Revenue growth 5Y-16.22%
Sales Q2Q%-36.9%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y79.8%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-7.15%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MED Yearly Revenue VS EstimatesMED Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 500M 1B 1.5B
MED Yearly EPS VS EstimatesMED Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MED. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MED. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MED Price Earnings VS Forward Price EarningsMED Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60

4.2 Price Multiples

  • The rest of the industry has a similar Price/Free Cash Flow ratio as MED.
Industry RankSector Rank
P/FCF 91.77
EV/EBITDA N/A
MED Per share dataMED EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. Dividend

5.1 Amount

  • MED has a Yearly Dividend Yield of 9.97%, which is a nice return.
  • MED's Dividend Yield is rather good when compared to the industry average which is at 1.61. MED pays more dividend than 97.22% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.80, MED pays a better dividend.
Industry RankSector Rank
Dividend Yield 9.97%

5.2 History

  • The dividend of MED decreases each year by -66.94%.
  • MED has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)-66.94%
Div Incr Years0
Div Non Decr Years0
MED Yearly Dividends per shareMED Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2 4 6

5.3 Sustainability

  • The earnings of MED are negative and hence is the payout ratio. MED will probably not be able to sustain this dividend level.
DP-1.04%
EPS Next 2YN/A
EPS Next 3YN/A
MED Yearly Income VS Free CF VS DividendMED Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

More info and screens

Find the best dividend stocksShow peers with best dividend

MEDIFAST INC

NYSE:MED (2/26/2026, 8:04:00 PM)

After market: 10.43 0 (0%)

10.43

-0.22 (-2.07%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)02-17
Earnings (Next)04-27
Inst Owners84.91%
Inst Owner Change-9.18%
Ins Owners3.3%
Ins Owner Change0%
Market Cap114.63M
Revenue(TTM)385.79M
Net Income(TTM)-18.67M
Analysts46.67
Price Target12.24 (17.35%)
Short Float %18.88%
Short Ratio7.89
Dividend
Industry RankSector Rank
Dividend Yield 9.97%
Yearly Dividend0.02
Dividend Growth(5Y)-66.94%
DP-1.04%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.14%
Min EPS beat(2)33.59%
Max EPS beat(2)46.69%
EPS beat(4)4
Avg EPS beat(4)84.74%
Min EPS beat(4)33.59%
Max EPS beat(4)199.01%
EPS beat(8)7
Avg EPS beat(8)105.41%
EPS beat(12)10
Avg EPS beat(12)86.59%
EPS beat(16)13
Avg EPS beat(16)72.42%
Revenue beat(2)2
Avg Revenue beat(2)3%
Min Revenue beat(2)0.75%
Max Revenue beat(2)5.26%
Revenue beat(4)4
Avg Revenue beat(4)4.71%
Min Revenue beat(4)0.75%
Max Revenue beat(4)8.75%
Revenue beat(8)7
Avg Revenue beat(8)2.97%
Revenue beat(12)11
Avg Revenue beat(12)3.64%
Revenue beat(16)15
Avg Revenue beat(16)3.64%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)207.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.3
P/FCF 91.77
P/OCF 16.7
P/B 0.58
P/tB 0.58
EV/EBITDA N/A
EPS(TTM)-0.65
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)0.11
FCFY1.09%
OCF(TTM)0.62
OCFY5.99%
SpS35.1
BVpS18.1
TBVpS18.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.53%
ROE -9.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.33%
FCFM 0.32%
ROA(3y)8.43%
ROA(5y)22.37%
ROE(3y)13.65%
ROE(5y)42.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0%
GM growth 5Y-0.9%
F-Score4
Asset Turnover1.56
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 39.42%
Cap/Sales 1.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.69
Quick Ratio 4.22
Altman-Z 4.42
F-Score4
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)49.18%
Cap/Depr(5y)160.46%
Cap/Sales(3y)1.1%
Cap/Sales(5y)1.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-132.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-650%
EPS Next Y79.8%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-35.96%
Revenue growth 3Y-37.74%
Revenue growth 5Y-16.22%
Sales Q2Q%-36.9%
Revenue Next Year-7.15%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-167.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-92.66%
FCF growth 3Y-80.85%
FCF growth 5Y-61.05%
OCF growth 1Y-71.96%
OCF growth 3Y-67.21%
OCF growth 5Y-45.69%

MEDIFAST INC / MED FAQ

What is the ChartMill fundamental rating of MEDIFAST INC (MED) stock?

ChartMill assigns a fundamental rating of 4 / 10 to MED.


Can you provide the valuation status for MEDIFAST INC?

ChartMill assigns a valuation rating of 1 / 10 to MEDIFAST INC (MED). This can be considered as Overvalued.


Can you provide the profitability details for MEDIFAST INC?

MEDIFAST INC (MED) has a profitability rating of 3 / 10.


Can you provide the financial health for MED stock?

The financial health rating of MEDIFAST INC (MED) is 9 / 10.